Welcome, visitor! [ Login



Dragon is developing an engineered version of the naturally occurring human protein thrombopoietin, TPO. This protein is produced mainly by the liver and stimulates the production of blood platelets and bone marrow platelet progenitor (!!±pre-platelet!!L) cells. Platelets are critical to blood clotting and wound healing, and are often diminished in patients receiving cancer chemotherapy, or in those with liver or other relevant diseases, causing thrombocytopenia. This condition can result in uncontrolled bleeding or bruising and is currently treated by high-cost blood transfusions.

The introduction of effective and potent platelet stimulating drugs will greatly improve the treatment of thrombocytopenia and could give rise to a market worth hundreds of millions of dollars. Such products may also increase platelet levels prior to blood donation in normal donors, or in surgery patients whose own blood is used for post-surgical transfusion.

TPO products are under development. Phase I/II randomized, placebo-controlled clinical trials have shown that they increase platelet counts when used prior to or subsequent to chemotherapy. They are also generally well tolerated. Dragon!|s TPO has been tested in animals and is now ready to enter phase I clinical trials in cancer patients. Our first regulatory approvals for this product are expected in 2005.

Dragon has developed a novel system for manufacturing TPO, using Pichia yeast. We expect this technology to produce better yields of TPO than other available production systems, resulting in lower unit costs.

buy steroids here

No Tags

3559 total views, 1 today


  • Dragon Ships EPO Internationally

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]

  • Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

    Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]

  • Dragon Announces Participation at Biopartnering Europe 2001

    Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]

  • Dragon Launches EPO Into the Brazilian Market

    Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil. Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon’s EPO in the Brazilian state of Minas, Gerais, which converts to […]

  • Dragon Signs Licensing Agreement for Korea

    Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) today announced that it has entered into a marketing and licensing agreement with Boryung Biopharma Company, Ltd. of Seoul, Korea for the distribution of recombinant Erythropoietin (EPO) in North and South Korea. According to the agreement, Boryung Biopharma will also be responsible for obtaining marketing for EPO from the […]

Dragon Pharma Suppliers

dragon pharma source
american steroids online
real dragon pharma supplier
dragon pharma for sale
dragon pharma legit supplier
buy dragon pharma
dragon pharma store
buy steroids
dragon pharma legit dragon pharma anabolics